Suciraslimab - Lonn Ryonn Pharma/SinoMab Bioscience Ltd
Alternative Names: SM-03Latest Information Update: 28 Jul 2024
At a glance
- Originator Lonn Ryonn Pharma; SinoMab Bioscience Ltd
- Class Antidementias; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action CD22 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Rheumatoid arthritis
- Phase II Non-Hodgkin's lymphoma; Systemic lupus erythematosus
- Phase I Alzheimer's disease; Sjogren's syndrome
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in China (IV, Infusion)
- 22 Nov 2023 Phase-I clinical trials in Alzheimer's disease in China (IV) prior to November 2023 (SinoMab Bioscience pipeline, November 2023)
- 22 Nov 2023 Phase-I clinical trials in Sjogren's syndrome in China (IV) prior to November 2023 (SinoMab Bioscience pipeline, November 2023)